Does itraconazole interact with nebivolol, and what monitoring or dose adjustments are required?

Itraconazole-Nebivolol Drug Interaction

Itraconazole significantly increases nebivolol plasma concentrations through CYP3A4 inhibition and should be used with extreme caution, requiring nebivolol dose reduction and close blood pressure monitoring.

Mechanism of Interaction

Itraconazole is a potent CYP3A4 inhibitor 1, while nebivolol is metabolized via CYP2D6 and to a lesser extent via CYP3A4 2. Although nebivolol's primary metabolic pathway is CYP2D6, the CYP3A4 pathway becomes clinically relevant when inhibited by strong inhibitors like itraconazole.

The FDA label for nebivolol explicitly states that "drugs that inhibit CYP2D6 can be expected to increase plasma levels of nebivolol" and recommends monitoring patients closely when co-administered with enzyme inhibitors 2. While this specifically references CYP2D6, the principle extends to CYP3A4 inhibition given nebivolol's dual metabolic pathways.

Clinical Significance

Expected Effects:

• Increased nebivolol exposure leading to enhanced beta-blockade
• Excessive blood pressure reduction (hypotension)
• Bradycardia (heart rate <60 bpm)
• Potential heart failure exacerbation in susceptible patients 2

Evidence from Similar Interactions:

The magnitude of this interaction can be substantial. When nebivolol was co-administered with fluoxetine (another CYP2D6 inhibitor), there was an 8-fold increase in AUC and 3-fold increase in Cmax for d-nebivolol 3. While itraconazole primarily inhibits CYP3A4 rather than CYP2D6, similar dramatic increases have been documented with other CYP3A4 substrates:

• Itraconazole increased felodipine (a calcium channel blocker) concentrations 6-8 fold 4
• Combined with gemfibrozil, itraconazole increased repaglinide exposure 19-fold 5

Management Algorithm

1. Risk Assessment Before Initiating Combination:

• Baseline blood pressure and heart rate
• Assess for pre-existing bradycardia (<60 bpm) or hypotension (SBP <100 mmHg)
• Evaluate for heart failure symptoms or left ventricular dysfunction
• Review for AV conduction abnormalities

2. Dose Adjustment Strategy:

If itraconazole must be added to existing nebivolol:

• Reduce nebivolol dose by 50-75% (e.g., from 10 mg to 2.5-5 mg daily) 2
• Monitor blood pressure and heart rate within 3-5 days of starting itraconazole
• Titrate nebivolol based on clinical response

If nebivolol must be added to existing itraconazole:

• Start with 2.5 mg daily (the lowest available dose) 2
• Titrate slowly at 2-week intervals only if needed
• Maximum dose should not exceed 10 mg daily (versus usual 40 mg maximum)

3. Monitoring Requirements:

First 2 weeks (critical period):

• Blood pressure and heart rate twice weekly
• Watch for symptoms: dizziness, fatigue, shortness of breath, cold extremities

Ongoing monitoring:

• Weekly blood pressure/heart rate checks for the first month
• Monthly thereafter while on combination therapy
• Consider itraconazole therapeutic drug monitoring 1, 6 - target trough >250 ng/mL for efficacy, but be aware higher levels may intensify the interaction

4. Warning Signs Requiring Immediate Action:

• Heart rate <50 bpm
• Systolic blood pressure <90 mmHg
• Symptomatic hypotension (dizziness, syncope)
• New or worsening dyspnea
• Signs of heart failure decompensation

Alternative Strategies

Consider Alternative Antifungal Agents:

If the interaction risk is unacceptable, consider:

• Amphotericin B formulations (no CYP interactions) 7
• Echinocandins (no CYP interactions)
• Fluconazole (weaker CYP3A4 inhibitor, though still requires caution)

Consider Alternative Beta-Blockers:

• Beta-blockers with less CYP metabolism (e.g., atenolol, nadolol - renally eliminated)
• However, this requires careful consideration of the specific indication for nebivolol

Special Populations

Elderly patients: Start with 2.5 mg nebivolol regardless of itraconazole co-administration; they are at higher risk for bradycardia and hypotension 2.

Renal impairment (CrCl <30 mL/min): Already requires 2.5 mg starting dose of nebivolol 2; combination with itraconazole may necessitate even lower or alternate-day dosing.

Hepatic impairment: Both drugs are hepatically metabolized. Moderate hepatic impairment already requires 2.5 mg nebivolol starting dose 2; avoid this combination in severe hepatic impairment 8.

Key Caveats

• The ACC/AHA/HRS guidelines 9 list itraconazole as a contraindicated or cautionary agent with multiple cardiovascular drugs due to CYP3A4 interactions
• Verapamil, another cardiovascular agent, is explicitly listed as having significant interactions with itraconazole 9, establishing precedent for concern with cardiovascular-antifungal combinations
• The interaction is bidirectional but asymmetric - itraconazole affects nebivolol more than nebivolol affects itraconazole
• Duration of itraconazole therapy matters: short courses (1-2 weeks) pose less cumulative risk than prolonged therapy (6-12 months) 10

This combination should only be used when the benefit of both medications clearly outweighs the risk of significant hemodynamic compromise.